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Serviç o de Gastrenterologia, Centro Hospitalar Universitário de Coimbra, Coimbra, Portugal
CIDES – Department of Health Information and Decision Sciences, Faculty of Medicine, University of Porto, Portugal
CINTESIS – Centre for Health Technology and Services Research, Porto, Portugal
Gastroenterology Department, Centro Hospitalar do Algarve, Portugal
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Background:  The  use  of  complementary  and alternative  medicines  is increasing  among  chronic  patients,
particularly  those  afflicted  with  inflammatory  bowel  diseases.
Aim:  This  study  aimed  to address  the prevalence  of  complementary  and  alternative  medicines  use  among
Portuguese  inflammatory  bowel  diseases’  patients.
Methods:  Patients  were  invited  to fill  an  anonymous  questionnaire  concerning  the use  of  complementary
and  alternative  medicines.
Results:  Thirty-one  per  cent  of  the  patients  reported  having  used  complementary  and  alternative
medicines  in  the  past,  whereas  12%  were  using  them  by the  time  the questionnaire  was  adminis-
tered.  Fifty-nine  per  cent  of  the  users  did  not  share  this  information  with  their physician,  whereas  14%
and  8%  discontinued  their  medication  and  periodical  examination,  respectively.  Steroids  prescriptionnflammatory bowel diseases (IBD) (OR  = 2.880)  and  a higher  instruction  level  (OR  = 3.669)  were  predictors  of complementary  and  alternative
medicines  use  in  this  cohort.
Conclusions:  Roughly  a third  of  Portuguese  IBD  patients  had  used  CAM.  Steroid  treatment  and  an academic
degree are  associated  with  CAM  use.  Given  the  potential  side  effects  and  interactions,  patient  information
about  the  benefits  and  limitations  of conventional  and  complementary  treatments  should  be  reinforced.
© 2017  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.∗ Corresponding author.
E-mail address: fasportela@gmail.com (F. Portela).
ttp://dx.doi.org/10.1016/j.dld.2016.12.031
590-8658/© 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All1. IntroductionInflammatory bowel diseases (IBD), which include Crohn’s dis-
ease (CD) and ulcerative colitis (UC), are lifelong immune-mediated
disorders characterized by a relapse and remitting course, and
 rights reserved.
















































Fig 1. Relative frequency of conventional th
articularly common in developed countries [1,2]. Whereas UC is
imited to the rectum and colon, CD can virtually affect any part
f the gastrointestinal tract (GI), although being more commonly
ound along the ileum and in the beginning of the colon. Despite this
nd other differences, CD and UC share a characteristic heavy bur-
en of symptomatology: rectal bleeding, abdominal pain, diarrhea
nd fatigue are some of the more conspicuous symptoms affecting
BD patients. So far, no curative therapies have been developed for
C or CD, and therefore the current management of these diseases
ims to control the symptoms and improve patients’ health-related
uality of life (HRQoL). This management relies on quite com-
lex therapeutic lines that can include steroids, anti-inflammatory
rugs (such as 5-aminosalicylic acid [5-ASA]), immunomodula-
ors (such as azathioprine [AZA] or anti-tumour necrosis factor
 [anti-TNF]), and bowel surgery. Understandably, both IBD and
he medications taken to control the burden of symptoms have a
igh impact on patients’ HRQoL and are associated with a higher
revalence of psychological disorders [3].
The awareness and interest in complementary and alterna-
ive medicines (CAM) has been raising among IBD patients. The
uropean Crohn’s and Colitis Organisation (ECCO) defines com-
lementary and alternative therapies according to their pattern
f use: complementary therapies are those that are used along-
ide with conventional medicine, whereas alternative therapies
re those that are used in the place of conventional medicine
1,2]. The holistic and self-healing nature of CAM is particularly
ttractive to chronic patients, as it is the popular notion that CAM
as no side effects. In the context of IBD, different techniques
nd products are commonly used, some of which have been the
ubject of laboratory tests and/or clinical trials: treatment with
elminths [4], gut-directed hypnotherapy [5–8], herbal medicines
8–12], acupuncture [8,13], nutritional strategies [8,14,15], exer-
ise [16], and antioxidant therapy [17] are a few of them. Some
f the results obtained in these trials are indeed promising –
or instance, the association of gut-directed hypnotherapy with a
educed IBD-related inflammation and an increase of HRQoL [6],
r the demonstration that Boswellia serrata gum resin and Plantago
vata seeds are as effective as 5-ASA in the treatment of UC [11].
owever, these results need to be interpreted with caution, as the
ack of high-quality data remains an issue in most CAM studies. The
fficacy and safety of CAM need to be evaluated by multicentric
nd double blind randomized controlled trials with large samples
efore definitive conclusions are drawn.
The knowledge of CAM utilization patterns among a certain
ommunity is absolutely necessary in order to prevent interac-
ions with conventional medicine, potential side effects and a
ecrease in therapeutic compliance. Although such an issue has
een approached in several countries of North America, Europees used among the studied IBD population.
and Asia, the picture in Portugal remains unknown, and the strong
impact of regional and cultural factors in CAM utilization prevents
the extrapolation of the results from other European countries. As
so, this study aimed to explore the use and attitudes of Portuguese
IBD patients toward CAM based on the results of an anonymous
survey.
2. Material and methods
2.1. Study population
IBD patients were recruited from APDI (Portuguese IBD patients’
association) and from 13 different university and community hos-
pitals between October 2011 and March 2012. Patients older than
18 years and with a confirmed diagnosis of UC, CD or unclassified
colitis were invited to participate in the study. These patients were
given a questionnaire containing 31 yes or no and multiple choice
questions focused on social-demographic aspects (gender, age,
instruction level and professional sector), clinical data, compliance,
and CAM use and attitudes. All questionnaires were anonymous
and self-administered, being afterwards returned by mail. The local
ethic committee has approved this study.
2.2. Statistical analysis
Categorical variables were described using absolute and rel-
ative frequencies, whereas continuous variables were described
using average, median, standard deviation, percentiles, and
minimum/maximum values. The Pearson Chi-square test was
used to test the independence of categorical variables. T and
Mann–Whitney tests were used to test the similarity of groups,
depending on whether their distribution was normal or not nor-
mal. Logistic regression was  employed to determine which factors
could independently predict the use of CAM. All tests were evalu-
ated considering a significance level of 5%. All data was arranged,
processed and analysed with SPSS
®
v.19.0 data (Statistical Package
for Social Sciences), whereas graphs were designed using Prism 7.
3. Results
3.1. Cohort characterization
A total of 750 questionnaires were distributed, and 442 were
returned and considered valid, which corresponds to a response
rate of 59%. Nine questionnaires (1.2%) were considered invalid due
to a lack of answers. The socio-demographic and clinical charac-
teristics of the study population are summarized in Table 1. Most
respondents were female (57%), were educated to a college degree






Age  (average, sd) 43 13








IBD  (n, %)
Ulcerative colitis 154 33
Crohn’s disease 299 65
Unclassified 8 2
Disease duration (median, P05–P95) 11 3–30
Hospital admissions (previous 5 years) (n, %)
None 253 56
1  90 20
2–5  94 21
>5  13 3
Bowel-related surgeries (previous 5 years)
(n, %) 96 22
(median, P05–P95) 1 (1–3)
Conventional therapy prescription (n, %)
Yes 329 76
Disease-related current well-being (n, %)
Ok 182 40
So-so 213 47
Not  ok 54 12
Very  bad 9 2
Have  you ever used alternative medicines because of your IBD? (n, %)
Yes 145 31
Do  you currently use alternative medicines because of your IBD? (n, %)
Yes 57 12
How  did you feel regarding your disease by the time you decided to use alternative medicines? (n, %)





























Not  ok 
Very  bad 
39%) and worked in the tertiary sector (79%). UC afflicted 33% of
he respondents, whereas 65% of them had a CD diagnosis and 2%
ad unclassified colitis. The median time of disease duration was
1 years, and 22% of all patients had undergone at least one bowel-
elated surgery in the previous five years. During the same time
eriod, 20 and 21% of all patients had one or two to five hospital
dmissions, respectively. Conventional therapies were prescribed
o a total of 76% of all respondents, and the distribution of those
herapies is depicted on Fig. 1: salicylates were the most commonly
rescribed medications (94% of the respondents had used them
n the past and 76% were using them by the time the question-
aire was administered), followed by immunosuppressors (47%
n the past and 34% by the time the questionnaire was  adminis-
ered). The prescription of steroids was relatively common in the
ve years preceding this study (41% of patients were on steroids),
ut by the time the questionnaire was administered only 11% of the
esponders were medicated with these drugs. Most patients (87%)
eported they were feeling at least partially well in relation to their
BD (Table 1).
A total of 145 patients (31%) of this cohort had used some kind of
AM to treat their IBD in the past, and 57 (12%) were still doing so by
he time this questionnaire was distributed (Table 1). The majority
f these patients (66%) stated that they were either “not ok” or “very
ad” in relation to their IBD by the time they decided to resort to
AM. The types of CAM used are depicted in Fig. 2, alongside with
heir relative frequencies. Herbal medicines and homeopathy were
he CAM types more frequently used by the patients in the past (39%
nd 42%, respectively), but only herbal medicines remained in the36 25
49 34
47 32
top preferences of the patients by the time the questionnaire was
addressed (46%), followed by vitamins intake (30%). Homeopathy
dropped down to a rate of utilization of 18%.
3.2. Attitudes and reasons leading to and following CAM
utilization
The inability of conventional medicine to improve their condi-
tion was the most commonly reported reason for patients to resort
to CAM (33%), and 72% did so after receiving advice from a col-
league, friend of family member (Fig. 3). A total of 67% of all CAM
users reported a positive outcome of the experience (i.e., they felt
“better” or “much better” after CAM use). The costs associated with
CAM were considerably high, with 66% of the CAM users spend-
ing over 50D per month in these medicines, and 41% reporting a
monthly cost over 100D . Indeed, financial reasons were the second
most cited reason for patients to abandon CAM after experiencing
it (44%), surpassed only by the absence of positive outcomes (51%).
In what concerns the potential effect of CAM use on conventional
medicine compliance, 86% and 92% of the respondents reported
to have maintained the conventional therapy and the periodical
examinations and analyses (respectively) during the time period
they were using CAM. Finally, 59% of the CAM users concealed this
information from their attending physician, and 71% did so because
they were afraid of the physician reaction (Fig. 3). Still, 85% of all
IBD patients would appreciate the opportunity to discuss CAM with
their physician.
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Fig. 2. Relative frequency of CAM therapies used among the CAM users.
Fig. 3. Motivational factors and attitudes of CAM use.
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Table 2
Association between the use of CAM and other demographic or disease-related variables.
Have you ever used MAC? p*
Yes No
Gender (n, %) 0.033
Male  48 (36) 140 (47)
Female 87 (64) 161 (53)
Age  (average, sd) 40 (13) 45 (14) <0.001**
Instruction level (n, %) <0.001
Mandatory 20 (14) 103 (33)
High-school 48 (33) 106 (34)
College 76 (53) 104 (33)
Professional sector (n, %) 0.063
Primary 1 (1) 9 (4)
Secondary 16 (13) 53 (21)
Tertiary 102 (86) 194 (76)
IBD  (n, %) 0.416
Ulcerative colitis 41 (29) 109 (35)
Crohn’s disease 99 (70) 199 (63)
Unclassified 2 (1) 6 (2)
Disease duration (median, P05–P95) 10 (4–27) 11 (3–30) 0.839***
Disease-related current well-being (n, %) 0.837
Ok  54 (39) 126 (40)
So-so 65 (46) 144 (46)
Not  ok 17 (12) 37 (12)
Very bad 4 (3) 5 (2)
Hospital admissions (previous 5 years) (n, %) 0.098
None  69 (50) 180 (59)
1  26 (19) 64 (21)
2–5 38 (28) 55 (18)
>5  5 (4) 7 (2)
Bowel-related surgeries (previous 5 years) 0.601
(n,  %) 32 (24) 63 (21)
(median, P05–P95) 2 (1–4) 1 (1–3) 0.318***
Conventional therapy prescription (n, %) 0.003
Yes 117 (85) 208 (71)
Conventional therapy during the last 5 years (n, %)
Biologics 0.088
Yes  36 (26) 57 (19)
Immunossupressors 0.024
Yes  77 (55) 133 (43)
Steroids 0.001
Yes  73 (53) 105 (36)
Salicilates 0.053
Yes  113 (91) 279 (96)
Current conventional therapy (n, %)
Biologics 0.043
Yes  30 (23) 45 (15)
Immunossupressors 0.358
Yes  48 (38) 97 (33)
Steroids 0.003
Yes  23 (18) 24 (8)
Salicilates 0.078
Yes  90 (70) 231 (78)















** T test for independent samples.
*** Mann–Whitney Test.
.3. The typical profile of a CAM user-associated variables and
redictors
Table 2 lists the socio-demographic and clinical variables inves-
igated and their association with CAM use. Neither disease type
or disease duration nor number of hospital admissions and bowel
urgeries are associated to CAM use in a significant fashion. On the
ther hand, patients who are younger (an average of 40 years old
s. 45, p < 0.001), females (64% of all users, p = 0.033), and that have
 college degree (53% of all users, p < 0.001) are particularly prone
o use CAM. Moreover, CAM use is more common among patients
o whom conventional therapy was prescribed (p = 0.003), partic-
larly those that were on immunosuppressors or steroids in the
ve years preceding the questionnaire administration (p = 0.024
nd p = 0.001, respectively), or on steroids or biologicals by thetime the questionnaire was administered (p = 0.003 and p = 0.043,
respectively).
A logistic regression was employed to discern which factors
were predictive of CAM use (Table 3). Although there were a num-
ber of significant variables on the univariate model (gender, age,
instruction level, hospital admissions in the previous five years and
prescription of conventional therapy, namely immunosuppressors,
steroids and biologicals), only two  of them retained their signifi-
cance in the multivariate model: instruction level and steroids use.
IBD patients educated to a college degree were more than three
times more likely to use CAM when compared to those with the
mandatory level of instruction (OR = 3.669, 95%CI: 1.554, 8.664),
whereas those that had used steroids at some time in the five years
preceding the administration of the questionnaire were almost
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Table  3
Multivariate analysis of variables associated with CAM use.
Univariate modela Multivariate modelb
OR CI95% p OR CI95% p
Gender
Male Ref
Female 1.576 1.037–2.396 0.033
Age, average (stdev) 0.972 0.957–0.988 <0.001
Instruction level
Mandatory Ref Ref
High-school 2.332 1.295–4.198 0.005 2.255 0.900–5.650 0.083
College 3.763 2.144–6.608 <0.001 3.669 1.554–8.664 0.003
Professional sector
Primary Ref
Secondary 2.717 0.320–23.100 0.360
Tertiary 4.732 0.591–37.871 0.143
IBD
Unclassified colitis Ref
Ulcerative colitis 1.128 0.219–5.818 0.885
Crohn’s disease 1.492 0.296–7.529 0.628
Disease duration 0.996 0.971–1.020 0.721
Disease-related current well-being
Ok Ref
So-so 1.053 0.683–1.624 0.814
Not  ok 1.072 0.556–2.068 0.835
Very bad 1.867 0.483–7.221 0.336
Hospital admissions (previous 5 years)
None Ref
1  1.060 0.622–1.807 0.831
2–5 1.802 1.095–2.966 0.020
>5  1.863 0.572–6.068 0.302
Bowel-related surgeries (previous 5 years)
Yes 1.138 0.701–1.847 0.601
No  Ref
How many surgeries? 1.219 0.779–1.908 0.386
Conventional therapy prescription
Yes 0.450 0.265–0.764 0.003
No  Ref
Conventional therapy during the last 5 years
Biologics
Yes 1.510 0.9.9–2.429 0.089
No  Ref
Immunosuppressors
Yes 1.583 1.060–2.364 0.025
No  Ref
Steroids
Yes 2.011 1.333–3.032 0.001 2.880 1.619–5.124 <0.001
No  Ref Ref
Salicilates




Yes 1.701 1.013–2.854 0.044
No  Ref
Immunosuppressors
Yes 1.225 0.795–1.887 0.358
No  Ref
Steroids
Yes 2.473 1.338–4.574 0.004
No  Ref
Salicilates








ote: Bold means significant (p < 0,05).
a Dependent variable: MAC  use.
b Dependent variable: MAC  use; independent variables: all of those that had a p v
hree times more likely to use CAM than those who  had not taken
ny steroids in that time period (OR = 2.880, 95%CI: 1.619, 5.124).. Discussion
The utilization of CAM seems to be rising among chronic
atients, particularly among those that suffer from IBD. But despiteelow 0.20 in the univariated model selected by the Forward method.
the common perception that CAM is safe, some of the products
employed may  have kidney and liver toxicity, and/or may  interact
with conventional therapeutics, decreasing their effect. The knowl-
edge on the patterns of CAM use is fundamental to tackle the issues
mentioned above. Such information was, to the best of our knowl-
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tudy aimed to assess CAM use and its underlying reasons and
ttitudes in these patients.
The comparison of the prevalence of CAM use among different
ountries or regions is often made difficult by a series of cultural
nd methodological issues. First of all, the definition of what fits
he CAM concept varies: products and practices such as probi-
tics, exercise, relaxation, vitamin supplementation and prayer are
onsidered to be CAM in a few studies but not in others. Under-
tandably, the CAM prevalence tends to be higher in the studies
hat pre-define a larger set of therapies as CAM. On the other hand,
any studies do not specify whether patients used CAM specifi-
ally to improve their IBD – some IBD patients may  have used CAM
or other reasons, such as psychological stress or to promote gen-
ral well-being. Finally, a number of studies do not clarify whether
heir prevalence values refer to “ever used” or “current use” of CAM.
till, the CAM utilization among Portuguese IBD patients seems
o be similar to that found across other South European coun-
ries (23.6%–28.2% in Italy [18,19] and 23.1% in Spain [20]), Korea
29.5%–30% [21,22]), UK (26% [23]) and Hungary (30.9–31.7% [24]).
n the other hand, the prevalence of CAM use seems to be higher
mong IBD patients from Germany (51.3%–52% [25,26]), France
65.6% [27]), Norway (30–49% [28,29]), Canada (21%–56% [30,31]),
ustralia (45.4% [32]) and New Zealand (44.1% [33]). Our results
re based on a 59% response rate which is less than what was
chieved in some papers [18,28] but similar to others [25]. The
act that patients were free to answer the questionnaires at home
nd returned them by mail may  have had a negative impact on
he response rate but, in our opinion, it was important to limit the
onstraints inherent to hospital environment.
Regarding the outcomes of CAM use, 67% of the respondents in
his study reported feeling “better” or “much better”. This value
s higher than that found among other studies that addressed this
arameter, which varied between 26% and 55.6% [20,21,23]. D’Inca
t al. has further analysed the specific reasons that underlie the
atients’ satisfaction with CAM, and observed that whether 45.5% of
AM users reported a general sense of well-being but without clini-
al effect, 39.7% and 21.8% actually experienced an improvement in
heir IBD symptoms and a reduction in the number of flares, respec-
ively [18]. It is important to notice that the positive effects of CAM
n this and other studies are self-reported, and are therefore the
esult of a complex interaction between physical and psychological
actors, where the placebo effect cannot be dismissed.
The preferences in terms of CAM type unveiled an interest-
ng pattern: whereas homeopathy, herbal medicine and Chinese
raditional medicine appear to have been popular in the time
eriod that preceded the questionnaire administration, herbal
edicine, vitamins, meditation and traditional Chinese medicine
ere the preferred therapies by the time the patients entered the
tudy. These results are not uncommon: homeopathy and/or herbal
edicines tend to rank high among the preferences of European
AM users [18–20,23–26,29,34]. On the other hand, probiotics tend
o be the preferred CAM in North America [30,31]. Once again,
hese differences may  result from a simple methodological bias:
ith a few exceptions, probiotics are not considered to be CAM
mong European studies (and therefore are not an option on the
uestionnaires).
The absence of improvement following conventional therapy
as the most cited reason for CAM users to try these thera-
ies (33%), followed by the possible side effects of conventional
herapies (15%) and by the inability of conventional medicine to
ure their disease (14%). This motivational context is similar to
hat observed in other studies in what concerns the so-called
ush-factors (i.e., factors that push a patient away from conven-
ional medicine) [19,26,30–32,34]. Unfortunately, we have failed to
nclude in our questionnaire the pull-factors (i.e.,  factors that pull a
atient toward CAM), such as the possibility to have a greater con- Disease 49 (2017) 388–396
trol over the disease and/or an active involvement in the treatment,
and the will to undertake a holistic and a more “natural” therapeu-
tic approach [26,30–32,34]. These factors are likely relevant in the
studied population, as 36% of the respondents chose “other rea-
sons” when asked about their motives to try CAM and facing only
push-factors as options.
The possible impact of CAM use on the adherence to conven-
tional medicine is an important issue: concerning the population
assessed in this study, 14% and 8% of the CAM users discontin-
ued medication and periodic examinations (respectively) during
the time period they were on CAM. These proportions are similar
to those found in other studies [18,20,22]. Not only are these val-
ues worrisome by themselves, but they can also conceal a darker
reality. In fact, one should keep in mind that this compliance is
self-reported. And if, on one hand, patients are not always willing
to admit they discontinued their medication, on the other hand,
the lack of adherence may  actually be unintended (and unnoticed
by patients). Indeed, Nguyen et al. have shown that CAM use was
associated with a less favorable adherence to conventional therapy,
but 97% of non-adherents reported that their attitude was  uninten-
tional [31]. Conversely, Weizman et al. concluded that CAM use was
not associated with a lack of adherence to conventional therapies
[30]. More studies are needed to clarify this issue and to develop
compliance-enhancing strategies for IBD patients, both CAM users
and non-users.
Doctor–patient communication and mutual trust is an unavoid-
able key aspect one has to consider when addressing CAM use. In
this study, 59% of CAM users did not disclose the fact that they
were using CAM to their physician, and 71% of them claimed they
did so because they were afraid of the MD  reaction. However, 85%
of all IBD patients in this cohort would appreciate the possibil-
ity to discuss CAM with their attending physician. This scenario is
transversal to different IBD populations: a considerable proportion
of CAM users choose not to disclose that information to their physi-
cian [25,30,32]. A qualitative study by Lindberg et al. suggested that
IBD patients would like to discuss CAM use with their physician,
but they do not initiate any conversation on this subject for fear
they would not be taken seriously [35]. In contrast, gastroenterol-
ogists were shown to have a generally positive attitude regarding
CAM: a study from Gallinger and Nguyen based on a web survey
reported that 68% of gastroenterologists believed that CAM could
be a good adjuvant in IBD therapy and 72% felt comfortable dis-
cussing it [36]; a qualitative study by Lindberg et al. reported that
health professionals believed CAM belonged within healthcare and
was relevant to conventional therapeutics [37]. Notwithstanding, a
common complaint among all gastroenterologists and other health
professionals was the lack of formal knowledge in the area. Given
the increasing importance and prevalence of CAM use, the intro-
duction of CAM-related topics in medical schools and workshops
of continuing medical education is absolutely necessary, and will
undoubtedly be a key step to facilitate doctor-patient communica-
tion in this particular subject.
The female gender, younger age, college education, previous use
of immunosuppressors and steroids, and current use of biologicals
and steroids were significantly associated with CAM use. College
instruction and previous use of steroids were actually indepen-
dent predictor factors of CAM use, with ORs of 3.669 and 2.880,
respectively. These relationships have been noticed before in
several studies and, opposite to what happens with other CAM
use features, seem to be transversal across different geographic
locations and IBD populations [18,19,22,24,26,28–30,32,33]. Other
factors associated with CAM use have been depicted in other stud-
ies, but those were either not explored or failed to be associated
with CAM use in the present study: evidence for a health-conscious
lifestyle, number of hospital admissions and consultations,
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ution of the disease, need for psychological support, presence
f extra-intestinal manifestations, permanent employment, higher
ncome and presence of co-morbidities [18–20,22,26,28,32,33,38].
Conventional therapies have known side effects, the fear of
hich may  lead patients to resort to CAM in the search of what
hey believe to be a more natural and less toxic approach. The
act that previous use of steroids was found as an independent
redictor of CAM use can be, at least in part, explained by the side
ffects profile of these drugs. Steroids can also be considered a sur-
ogate mark of a moderate or severe disease, which has been linked
o CAM use in other studies [18,19,22,29]. On the other hand, the
ssociation of CAM use to a high level of instruction is quite com-
on  and may  be related to the fact that college-educated patients
re more resourceful and more likely to explore their IBD disease
rom different perspectives. Moreover, the use of CAM gives them a
ense of control over their disease. Additionally, they are also more
ikely to be able to afford CAM: in fact, and as shown by this and
ther studies, CAM use is rather expensive [18,27]. The association
f CAM use with permanent employment and higher income seen
n other studies supports this hypothesis [22,32,33]. Still, the rela-
ionship between college education and the use of therapies mostly
eprived of scientific support merits further studies.
This study was based on an anonymous questionnaire that was
istributed across the entire country (rural and urban areas) and
ncluded patients in different stages and with different severity of
he diseases (patients were recruited not only from medical consul-
ations but also from the Portuguese association of IBD patients). It
as, however, a few limitations that should be noticed. One of them
s inherent to all questionnaire-based CAM assessments – the lack
f consistency between the questionnaires administered in differ-
nt countries makes their comparisons difficult or even impossible.
he development and national-validation of an international CAM
uestionnaire with a precise definition of what should be consid-
red CAM [39], as well as the throughout characterization of the
opulation enrolled, are key steps to solve these issues. Another
imitation refers to the fact that the studied patients were in part
ecruited from conventional medicine care centers: satisfied users
f CAM are unlikely to attend these centers, which introduces a
ias in the sampling process. The disease status and CAM improve-
ents were self-reported and not objectively evaluated – this is
n unavoidable consequence of keeping the questionnaires anony-
ous; however, it does prevent one to identify placebo effects and
nflammatory bowel syndrome-related worsening of symptoms.
inally, the questionnaire was not previously validated, it did not
xplore positive motivational factors, and we had no information
n the patients’ psychological state of mind and HRQoL.
As a global conclusion, the CAM use patterns of IBD patients
n Portugal match those previously found among other European
ountries: the typical user is a young female with a college educa-
ion and an history of steroids prescription, whereas the preferred
AM type is herbalism. The prevalence is rather high and is intrin-
ically linked with the perceived inability of the conventional
edicine to produce positive outcomes. Patient-doctor communi-
ation is an issue: patients would like to discuss CAM with their
hysicians, but they fear their reaction and end up not disclos-
ng CAM use. Medicine faculties and continuing medical education
hould invest in disseminating formal knowledge on CAM, and
hysicians should improve their empathy and understand the
enefits of an integrative healthcare, including conventional and
on-conventional therapies. This would likely enhance patients’
ompliance and solve possible CAM-related adherence issues.onflict of interest
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